Search Results - "Rind, David M"

The FDA and Gene Therapy for Duchenne Muscular Dystrophy by Rind, David M

“…This Viewpoint examines the appropriateness of FDA accelerated approval of novel gene therapies to treat boys with Duchenne muscular dystrophy following…”
Get full text

Should We Screen for Type 2 Diabetes? by Rind, David M

Get full text

A network meta-analysis of KarXT and commonly used pharmacological interventions for schizophrenia by Wright, Abigail C., McKenna, Avery, Tice, Jeffrey A., Rind, David M., Agboola, Foluso

“…Dopaminergic antipsychotics for schizophrenia have modest effects on symptoms and can cause important side effects. KarXT is an investigational drug for…”
Get full text

How Do the Institute for Clinical and Economic Review’s Assessments of Comparative Effectiveness Compare With the German Federal Joint Committee’s Assessments of Added Benefit? A Qualitative Study by DiStefano, Michael J., Pearson, Steven D., Rind, David M., Zemplenyi, Antal

“…We compared the Institute for Clinical and Economic Review’s (ICER) ratings of comparative clinical effectiveness with the German Federal Joint Committee’s…”
Get full text

Grading of recommendations assessment, development, and evaluation concept article 5: addressing intransitivity in a network meta-analysis by Brignardello-Petersen, Romina, Tomlinson, George, Florez, Ivan, Rind, David M., Chu, Derek, Morgan, Rebecca, Mustafa, Reem A., Schünemann, Holger, Guyatt, Gordon H.

“…This article describes considerations for addressing intransitivity when assessing the certainty of the evidence from network meta-analysis (NMA) using the…”
Get full text

The Cost-Effectiveness of Remdesivir for Hospitalized Patients With COVID-19 by Whittington, Melanie D., Pearson, Steven D., Rind, David M., Campbell, Jonathan D.

“…This study aimed to estimate the cost-effectiveness of remdesivir, the first novel therapeutic to receive Emergency Use Authorization for the treatment of…”
Get full text

A guide for health professionals to interpret and use recommendations in guidelines developed with the GRADE approach by Neumann, Ignacio, Santesso, Nancy, Akl, Elie A, Rind, David M, Vandvik, Per Olav, Alonso-Coello, Pablo, Agoritsas, Thomas, Mustafa, Reem A, Alexander, Paul Elias, Schünemann, Holger, Guyatt, Gordon H

“…Abstract An increasing number of organizations worldwide are using new and improved standards for developing trustworthy clinical guidelines. One of such…”
Get full text

The impact of capping health system cost savings on the projected cost-effectiveness of etranacogene dezaparvovec compared with factor IX prophylaxis for the treatment of hemophilia B by Sarker, Jyotirmoy, Tice, Jeffrey A, Rind, David M, Pearson, Steven D, Walton, Surrey M

“…This viewpoint discusses cost-effectiveness estimates for EtranaDez, a gene therapy for hemophilia B, using the Institute for Clinical and Economic Review's…”
Get full text

Informing the United States Medicare Drug Price Negotiation for Apixaban and Rivaroxaban: Methodological Considerations for Value Assessments Many Years After Launch by Richardson, Marina, Wright, Abigail C., Tice, Jeffrey A., Rind, David M., Seidner, Matt, Emond, Sarah, Pearson, Steven D.

“…To demonstrate how health technology assessment methods can be used to support Medicare’s price negotiations for apixaban and rivaroxaban. Following the…”
Get full text

Cost-Effectiveness of Nadofaragene Firadenovec and Pembrolizumab in Bacillus Calmette-Guérin Immunotherapy Unresponsive Non–Muscle Invasive Bladder Cancer by Joshi, Mrinmayee, Atlas, Steven J., Beinfeld, Molly, Chapman, Richard H., Rind, David M., Pearson, Steven D., Touchette, Daniel R.

“…Nadofaragene firadenovec is a gene therapy for bacillus Calmette-Guérin (BCG)–unresponsive non–muscle-invasive bladder cancer (NMIBC) undergoing Food and Drug…”
Get full text

Mavacamten for hypertrophic cardiomyopathy: effectiveness and value: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum by Beinfeld, Molly, Wasfy, Jason H, Walton, Surrey, Sarker, Jyotirmoy, Nhan, Emily, Rind, David M, Pearson, Steven D

Get full text

GRADE concept 6: a novel application of external indirect evidence into GRADE ratings of evidence certainty in network meta-analysis by Hao, Qiukui, Gao, Ya, Zhao, Yunli, Murad, M Hassan, Mustafa, Reem, Ansari, Mohammed T, Schünemann, Holger J, Rind, David M, Brignardello-Petersen, Romina, Guyatt, Gordon

“…We describe how consideration of external evidence may play an important role in judging certainty in the process of establishing the certainty of the…”
Get full text

The effectiveness and value of aducanumab for Alzheimer’s disease: A summary from the Institute for Clinical and Economic Review’s California Technology Assessment Forum by Synnott, Patricia G, Whittington, Melanie D, Lin, Grace A, Rind, David M, Pearson, Steven D

Get full text

The effectiveness and value of midomafetamine-assisted psychotherapy for posttraumatic stress disorder by Nikitin, Dmitriy, Mustafa, Reem A, McQueen, Brett, Zemplenyi, Antal, DiStefano, Michael J, Nhan, Emily, Kayali, Yasmine, Richardson, Marina, Rind, David M, Pearson, Steven D, Agboola, Foluso

Get full text

Medications for obesity management: Effectiveness and value: A summary from the Institute for Clinical and Economic Review’s New England Comparative Effectiveness Public Advisory Council by Atlas, Steven J, Kim, Kibum, Nhan, Emily, Touchette, Daniel R, Moradi, Ashton, Agboola, Foluso, Rind, David M, Beaudoin, Francesca L, Pearson, Steven D

Get full text

The effectiveness and value of sotatercept for pulmonary arterial hypertension: A summary from the Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council by Nikitin, Dmitriy, Lin, Grace A, Whittington, Melanie D, Nhan, Emily, Kayali, Yasmine, Rind, David M, Pearson, Steven D, Agboola, Foluso

Get full text

The effectiveness and value of AMX0035 and oral edaravone for amyotrophic lateral sclerosis: A summary from the Institute for Clinical and Economic Review's Midwest Comparative Effectiveness Public Advisory Council by Nikitin, Dmitriy, Makam, Anil N, Suh, Kangho, McKenna, Avery, Carlson, Josh J, Richardson, Marina, Rind, David M, Pearson, Steven D

“…Funding for this summary was contributed by Blue Cross Blue Shield of MA, California Healthcare Foundation, The Patrick and Catherine Weldon Donaghue Medical…”
Get full text

JAK inhibitors and monoclonal antibodies for the treatment of atopic dermatitis: effectiveness and value by Agboola, Foluso, Atlas, Steven J, Brouwer, Elizabeth, Carlson, Josh J, Hansen, Ryan N, Herron-Smith, Serina, Nhan, Emily, Rind, David M, Pearson, Steven D

“…Funding for this summary was contributed by Arnold Ventures, The Donaghue Foundation, Harvard Pilgrim Health Care, and Kaiser Foundation Health Plan to the…”
Get more information

The effectiveness and value of emicizumab and valoctocogene roxaparvovec for the management of hemophilia A without inhibitors by Agboola, Foluso, Rind, David M, Walton, Surrey M, Herron-Smith, Serina, Quach, Danny, Pearson, Steven D

“…Funding for this summary was contributed by Arnold Ventures, California Health Care Foundation, The Donaghue Foundation, Harvard Pilgrim Health Care, and…”
Get more information

Cost-effectiveness of oral semaglutide added to current antihyperglycemic treatment for type 2 diabetes by Guzauskas, Gregory F, Rind, David M, Fazioli, Katherine, Chapman, Richard H, Pearson, Steven D, Hansen, Ryan N

“…Oral semaglutide is the first oral formulation of a glucagon-like peptide 1 (GLP-1) receptor agonist to be approved in the United States for glycemic control…”
Get full text